Skip to main content

Table 1 Summary of the main characteristics of the therapeutic strategies described in this review

From: A cure for AIDS: a matter of timing?

  Notable Results Stage Safety Scalability
ART during acute infection Long-term post-therapy viral load control in a minority of individuals [16, 17, 2330]. Clinical/pre-clinical High Low (few patients are detected HIV+ at acute infection)
Viral reactivation with HDACI’s Possible disruption of latency [48, 49, 5355]. No viral reservoir reduction [49]. Clinical/pre-clinical Medium High
Viral reactivation with cytokines IL-7 might disrupt latency but replenishes the viral reservoir [5759]. Clinical Medium Medium/high
Gene therapy for disruption of CCR5 Mixed impact on viral load (depending on the genetic background) [66]. Possible immunologic improvement [67]. Clinical Medium (long-term effects unknown) Very low
Allogeneic stem cell transplant Likely sterilizing cures in the second “Berlin Patient” [60, 61, 63] and in the “Boston Patients” [68, 69]. Clinical Very low Very low
Addition of auranofin and BSO to ART Long-term post-therapy control in chronically SIVmac251 infected macaques [74, 81]. Late pre-clinical Medium/high (good safety profile for individual drugs in humans) High
Therapeutic vaccine with whole virus-pulsed dendritic cells Post-therapy viral load control in a subset of macaques [88]. Viral load and viral load set-point reduction in a subset of ART-naïve [89, 90] and ART-treated patients [91], respectively Clinical High Medium
Administration of broadly neutralizing antibody/ies Long-term post-therapy control in chronically SHIV(env) infected macaques starting from low viral loads [95] Late pre-clinical High High
  1. In square brackets are the references describing the main results for each strategy.